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INTRODUCTION
It is observed that patients with moderate to severe chron-
ic kidney disease (CKD) demonstrate profoundly low levels
of 1,25-dihydroxyvitamin D (1,25D) and are also at a high
risk of 25-hydroxyvitamin D (25D) deficiency (1, 2). Some
observational studies have revealed that active vitamin D
therapy is independently associated with improved survival
among hemodialysis (HD) patients (3, 4). Moreover, it was
recently reported that decreased 25D levels are also associat-
ed with increased early overall or cardiovascular (CV) mortali-
ty among incident HD patients (5). These results suggest that
vitamin D insufficiency is directly related to CV outcome in
HD patients. We investigated the relationship of the levels
of 25D and 1,25D in the blood with those of cardiac troponin
T (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-
pro-BNP)-biochemical surrogates of CV outcome in HD pa-
tients (6-9).
MATERIALS AND METHODS
Patients
A total of 95 chronic HD patients from our renal unit were
screened. The inclusion criteria were: 1) maintenance HD
for more than 3 months; 2) no ischemic heart disease (IHD)
confirmed by electrocardiography (ECG) or coronary angiog-
raphy; 3) no recent chest pain or discomfort suggesting IHD;
4) no dyspnea on exertion (New York Heart Association func-
tional class II or above) or orthopnea; 5) no pulmonary edema
detected by chest radiography; 6) ejection fraction of at least
40% as indicated by the latest echocardiography; 7) no cere-
brovascular, peripheral vascular, chronic obstructive pulmonary,
chronic liver or malignant disease; 8) no active vitamin D
therapy. After screening, 65 patients were recruited for the
study. The study was approved by the local Institutional Review
Board and all the subjects provided their informed consent.
Clinical and laboratory measurements
This study was conducted in summer (August 2007). We
recorded the clinical characteristics, including gender, age,
causes of end stage renal disease (ESRD), duration of HD,
height, dry weight and pre/post-HD blood pressure (BP).
Laboratory analyses were performed prior to the first HD ses-
sion of the week; they included determination of 25D, 1,25D,
cTnT, NT-pro-BNP, hemoglobin, cholesterol, albumin, blood
urea nitrogen (BUN), creatinine, alkaline phosphatase, total
calcium, phosphate, intact parathyroid hormone (iPTH), and
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Vitamin D Levels and Their Relationship with Cardiac Biomarkers in
Chronic Hemodialysis Patients
Vitamin D insufficiency may be associated with cardiovascular (CV) mortality in HD
patients. To test this hypothesis, we cross-sectionally measured 25-hydroxyvitamin
D (25D), 1,25-dihydroxyvitamin D (1,25D), cardiac troponin T (cTnT), and N-termi-
nal pro-B-type natriuretic peptide (NT-pro-BNP) in chronic HD patients. Sixty-five
patients (M:F=31:34, age 52.2±13.2 yr, DM 41.5%) were selected. Along with the
expected low levels of 1,25D, 59 (90.8%) patients had 25D insufficiency (<30 ng/mL)
among whom 15 (23.1%) were 25D deficient (<10 ng/mL). The 25D levels showed
a negative correlation with cTnT levels (Spearman’s ρ =-0.44, p<0.01) but not with
NT-pro-BNP levels (Spearman’s ρ =-0.17, p=0.17). The 1,25D levels, however, did
not show any relationship with either cTnT or NT-pro-BNP. In multivariate analysis,
being male and having low levels of 25D were independent risk factors associated
with cTnT elevation (β =0.44, p<0.01 and β =-0.48, p<0.01, respectively). In conclu-
sion, not only 1,25D but also 25D are commonly decreased in HD patients. Lower
25D levels appear to be associated with cTnT elevation, predicting worse CV out-
come, and are possible to involve cardiac hypertrophy or coronary artery disease.
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Accepted : 19 December 2008high-sensitivity C-reactive protein (hs-CRP). Total serum cal-
cium levels were corrected using the serum albumin level. Sin-
gle pool Kt/V (spKt/V) and normalized protein equivalent
of total nitrogen appearance (nPNA) were calculated by the
three-point method of the urea kinetic model. Left ventric-
ular hypertrophy (LVH) was estimated by the Sokolow-Lyon
voltage (SV1 plus RV5 or V6 in ECG) (10).
The blood samples for 25D, 1,25D, cTnT, and NT-pro-
BNP determination were immediately centrifuged and the
serum stored at -70℃. The samples were analyzed simulta-
neously. 25D and 1,25D were estimated using radioimmunoas-
say (Biosource, Nivelles, Belgium and Immunodiagnostic
System Inc., AZ, U.S.A.). The manufacturer’s instructions
stated the ranges of 25D and 1,25D in healthy controls to
be 7.6-75 ng/mL and 20.2-46.2 pg/mL, respectively. NT-
pro-BNP was estimated using the Elecsys proBNP immunoas-
say (Roche Diagnostics, Indianapolis, IN, U.S.A.). cTnT was
estimated using a third-generation immunoassay (Elecsys
Troponin T STAT immunoassay; Roche Diagnostic, Indi-
anapolis, IN, U.S.A.).
Statistical analysis
Categorical variables were expressed as percentages and
continuous variables as the mean±standard deviation (SD).
Because 25D, 1,25D, NT-pro-BNP, cTnT, and hs-CRP were
positively skewed, they were expressed as medians (interquar-
tile range, IQR). The correlation between these variables was
verified by Spearman’s correlation analysis. For risk factor anal-
ysis, univariate and multivariate regression analyses were per-
formed after log transformation (log10) of the skewed data, as
appropriate. A multivariate regression analysis was performed
using a stepwise approach, by constructing a model based
on covariates (p<0.10) related to cTnT as indicated by the
univariate analysis. The analyses were conducted using the
SPSS software, version 13.0 (SPSS Inc., Chicago, IL, U.S.A.).
pvalue lower than 0.05 was considered statistically significant.
RESULTS
25D and 1,25D levels in HD patients
Baseline characteristics and laboratory data of 65 patients
are shown in Table 1. The median 25D concentration was
14.6 ng/mL (IQR 10.4-21.6). Thirty (46.1%) patients had
1,25D levels below the detection limit (<3.0 pg/mL), and
the median 1,25D concentration was 3.1 pg/mL (IQR 3.0-
4.3). The distributions of 25D and 1,25D are shown in Fig. 1.
Fifty-nine (90.8%) patients were identified with 25D insuf-
ficiency (<30 ng/mL) and 15 (23.1%) with 25D deficiency
(<10 ng/mL) (5). Although there is no cutoff value for 1,25D
deficiency, our patients had much lower levels compared with
the range of 20.2-46.2 pg/mL in healthy controls provided
by the manufacturer. The 1,25D concentration was weakly
but significantly related to 25D concentration (Spearman’s
ρ =0.36, p<0.01).
25D/1,25D levels and mineral/nutritional parameters
Mineral parameters, including corrected total calcium, phos-
phate, and iPTH levels correlated poorly with both 25D and
1,25D levels (Table 2). This suggests that although serum
levels of calcium, phosphorus, and iPTH are biologically linked
with vitamin D metabolism and are traditionally used to
identify vitamin D deficiency, this relationship is not appar-
ent in HD patients. Among the nutritional parameters, 25D
levels correlated with serum albumin (ρ =0.47, p<0.01) and
creatinine (ρ =0.42, p<0.01) but 1,25D levels did not.
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Data are expressed as mean±standard deviation or median (interquatile
range) as appropriate.
DM, diabetes mellitus; BMI, body mass index; HD, hemodialysis; PTH,
parathyroid hormone; hsCRP, high-sensitivity C-reactive protein; spKt/V,
single-pool Kt/V; nPNA, normalized protein equivalent of total nitrogen
appearance; 25D, 25-hydroxyvitamin D; 1,25D, 1,25-dihydroxyvitamin D.
Age (yr) 52.2±13.2
Gender M:F=31:34
DM (%) 41.5%
BMI (kg/m
2) 22.8±3.0
HD duration (months) 32±33
Corrected total calcium (mg/dL) 9.0±0.7
Phosphate (mg/dL) 4.6±1.7
Intact PTH (pg/mL) 59 (26-116)
Total cholesterol (mg/dL) 136±34
Albumin (g/dL) 3.9±0.4
Creatinine (mg/dL) 10.2±2.9
hsCRP (mg/dL)  0.04 (0.02-0.14)
spKt/V 1.5±0.3
nPNA (g/kg/day) 1.0±0.3
25D (ng/mL) 14.6 (10.4-21.6)
1,25D (pg/mL) 3.1 (3.0-4.3)
Table 1. Baseline characteristics and laboratory data (n=65)
25D, 25-hydroxyvitamin D; 1,25D, 1,25-dihydroxyvitamin D; tCa, total
calcium; iPTH, intact parathyroid hormone; nPNA, normalized protein
equivalent of total nitrogen appearance.
Corrected tCa -0.08 0.53 0.04 0.74
Phosphate 0.10 0.44 0.09 0.47
iPTH 0.20 0.12 0.13 0.32
Cholesterol 0.05 0.68 -0.21 0.10
Albumin 0.47 <0.01 0.03 0.84
Creatinine   0.42 <0.01 -0.02 0.87
nPNA 0.22 0.10 0.06 0.65
25D 1,25D
Spearman’s ρ p value Spearman’s ρ p value
Table 2. Correlation between 25D/1,25D and mineral/nutritional
parameters (n=65)Relationship between 25D/1,25D and cTnT/NT-pro-BNP
The median cTnT concentration was 0.02 ng/mL (IQR
0.01-0.04), and the median NT-pro-BNP concentration was
4,165 pg/mL (IQR 1,625-11,865). The 25D level was neg-
atively correlated with cTnT levels (ρ =-0.44, p<0.01) but not
with NT-pro-BNP levels (ρ =-0.17, p=0.17) (Fig. 2). How-
ever, 1,25D levels did not show any relationship with either
cTnT or NT-pro-BNP (ρ =-0.14, p=0.27 and ρ =-0.25, p=0.06,
respectively). Because pre-HD cTnT and NT-pro-BNP level
might have been influenced by a degree of volume overload,
we analyzed the effect of ulrafiltration amount/dry weight
(UF/DW) on both parameters. If determined DW was opti-
mal, UF/DW could represent excessive fluid accumulation
for inter-dialytic period. cTnT or NT-pro-BNP level was
not associated with UF/DW (ρ =-0.01, p=0.95 and ρ =0.17,
p=0.18, respectively), which meant that the relationship be-
tween 25D or 1,25D and cTnT or NT-pro-BNP level was
not confounded by UF/DW.
We analyzed the risk factors for elevated cTnT levels, includ-
ing the following variables: 25D concentration, age, gender,
diabetes as a cause of ESRD, HD duration, body mass index
(BMI), pre/post-HD systolic and diastolic BP, hemoglobin,
cholesterol, albumin, BUN, creatinine, alkaline phosphatase,
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Fig. 1. Distribution of 25D and 1,25D in the study population (n=65). Median 25D concentration was 14.6 ng/mL (IQR 10.4-21.6), and medi-
an 1,25D concentration was 3.1 pg/mL (IQR 3.0-4.3).
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Fig. 2. Relationship between 25D concentration and cTnT/NT-pro-BNP levels (n=65). 25D concentration shows negative correlation with
cTnT levels but not with NT-pro-BNP levels.
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Spearman’s rho=-0.17, p=0.17corrected total calcium, phosphate, iPTH, hs-CRP, spKt/V,
nPNA, the Sokolow-Lyon voltage and UF/DW. It was observed
that males had higher cTnT levels than females (0.03 ng/mL
[IQR, 0.01-0.05]vs. 0.01 ng/mL [IQR, 0.01-0.02], p=0.01).
Diabetic patients had higher cTnT levels than the others (0.04
ng/mL [IQR, 0.01-0.06] vs. 0.01 ng/mL [IQR, 0.01-0.03],
p<0.01). In univariate regression analysis, log 25D, log iPTH,
log hsCRP, spKt/V, and nPNA showed a correlation with
log cTnT (pvalue<0.1). Furthermore, in a multivariate regres-
sion model including age, gender, diabetes, and the above
variables, being male and having low log 25D concentration
were independent risk factors associated with an increase in
the log cTnT value (β =0.44, p<0.01 and β =-0.48, p<0.01,
respectively) (Table 3).
DISCUSSION
The present study showed that not only 1,25D but also
25D were profoundly insufficient in Korean HD patients.
Lower serum levels of 25D were associated with increased
cTnT levels but not with increased NT-pro-BNP levels; this
finding was independent of age, diabetes, standard nutrition-
al and inflammatory factors, and mineral parameters. 1,25D,
the biologically active form of vitamin D was not related to
both cTnT and NT-pro-BNP. 
Observations from previous studies suggest that 25D insuf-
ficiency or deficiency is common in CKD patients. In the
United States, only 29% and 17% of patients with moder-
ate and severe CKD (1), and 22% of incident HD patients
had a sufficient 25D level (>30 ng/mL) (5). Our results show
that the median 25D concentration was 14.6 ng/mL (IQR
10.4-21.6), and only 9.2% patients showed 25D levels above
30 ng/mL. Comparing the result of incident HD patients in
the United States (5) with those in Korea, 25D deficiency seems
to be more frequent in our cohort despite the younger age
(51.6±12.9 vs. 63±15 yr) and absence of black patients
(0 vs. 32%). It should be noted that 25D levels in this study
were measured in summer, when sunlight exposure is the
highest for the year. Hence, the severity of 25D insufficien-
cy may be more profound in winter. 25D is derived from
conversion of calciferol (cholecalciferol or ergocalciferol) in
the liver. Cholecalciferol is produced by the skin on exposure
to UVB light, and cholecalciferol or ergocalciferol can be
obtained from dietary sources such as fortified cereals, dairy
products, fish oil, and egg yolk. In CKD patients, decrease
in both sunlight exposure and dietary intake may be a main
cause of 25D insufficiency. However, it is noteworthy that
while 25D production by the liver does not depend on nor-
mal renal function, the cutaneous production of cholecalcif-
erol is impaired in uremia (11). As expected, 1,25D level was
severely decreased. 1,25D level was partially related with 25D
level (ρ =0.36, p<0.01). In ESRD, because 1α -hydroxylase is
deficient and is not normally regulated, 1,25D level may be
more dependent on the precursor level, 25D.
We demonstrated that 25D levels are negatively associat-
ed with cTnT levels, and this finding is independent of other
CV risk factors. Usually, cTnT is considered as a marker of
ongoing myocardial damage (12) and NT-pro-BNP, a mark-
er of left ventricular overload (13); both have a significant
prognostic value in predicting CV mortality in patients with
ESRD (6-9). In this regard, our observation is encouraging
from 2 viewpoints. First, the 25D insufficiency may be relat-
ed to high CV mortality in HD patients. Second, the 25D
insufficiency may also be partly responsible for myocardial
hypertrophy or coronary artery disease in HD patients. It is
worth noting that the elevation of cTnT levels was correlat-
ed with 25D levels but not with 1,25D (bioactive form of
vitamin D) levels. In our opinion, the decrease in 25D may
cause more profound 1,25D deficiency as describe above, and
then may result in cTnT elevation. The reason that 1,25D
level was not associated with cTnT level might be that almost
all patients had very low concentration of 1,25D, which was
below the limit of detection in a half of the patients. How-
ever, it is speculated that 25D itself has important biologi-
cal effects on the CV system. Although kidney is the major
organ that converts 25D to 1,25D by 1α -hydroxylase, many
other cells, including vascular smooth muscle and endothe-
lial cells, also express 1α -hydroxylase (14, 15). 1,25D, syn-
thesized from the circulating 25D in these cells, binds the
local vitamin D receptor (VDR) in the autocrine/paracrine
pathways. 25D circulates at a concentration about 1,000-fold
higher than that of 1,25D; this suggests that adequate 25D
levels may also be necessary, especially for cells that rely on
autocrine/paracrine pathways. However, this aspect will require
investigation.
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Because cTnT, iPTH, hs-CRP, and 25D are positively skewed, a log trans-
formation was performed for them before analysis. β is standardized coef-
ficient of regression. 
cTnT, cardiac troponin T; iPTH, intact parathyroid hormone; hs-CRP, high-
sensitivity C-reactive protein; spKt/V, single-pool Kt/V; nPNA, normal-
ized protein equivalent of total nitrogen appearance; 25D, 25-hydrox-
yvitamin D.
Univariate analysis
Age 0.16 0.20
Log iPTH -0.33 <0.01
Log hs-CRP 0.27 0.03
spKt/V -0.30 0.02
nPNA -0.28 0.03
Log 25D -0.36 <0.01
Multivariate analysis
Male 0.44 <0.01
Log 25D -0.48 <0.01
γ
2 0.31
SEE 0.33
Risk factors β p value
Table 3. Univariate and multivariate regression analysis for log
cTnT levels (n=65)In a prospective cohort of HD patients, vitamin D insuf-
ficiency was associated with an increased rate of early CV
mortality (5). Observational studies have indicated that CV
outcomes associated with active vitamin D therapy have a
significant advantage (3, 4). On the other hand, the recent
meta-analysis of 76 randomized trials found no good evidence
that vitamin D compounds reduced risk for death, bone pain,
vascular calcification, or need for parathyroidectomy in patients
with CKD (16). Hence, the available evidences are debatable,
and it is difficult to conclude whether there exists a definite
relationship between vitamin D insufficiency and CV mor-
tality, and whether active vitamin D therapy would be favo-
urable for reducing CV mortality. However, some mechanisms
may explain the link between vitamin D insufficiency and
elevated cTnT levels. First, vitamin D may suppress myocar-
dial hypertrophy; calcitriol was shown to antagonize endothe-
lin-stimulated hypertrophy in neonatal rat cardiomyocytes
(17). Clinical studies have revealed that intravenous calcitri-
ol produces a significant regression of the left ventricular mass
index and concomitant reductions in plasma iPTH, angiotensin
II, and arterial natriuretic peptide (18). However, it is unclear
whether vitamin D reduces cardiac hypertrophy by itself via
VDR or by reducing iPTH. Second, vitamin D may affect
arterial cells. As mentioned above, vascular smooth muscle
cells and endothelial cells have 1α -hydroxylase and express
VDR (14, 15). Putative vascular effects of vitamin D are wide-
ranging, including modulation of smooth muscle cell pro-
liferation (19, 20), inflammation (21), and thrombosis (22).
Hence, vitamin D insufficiency may be involved in the pro-
gression of coronary artery disease. In this study, unlike the
cTnT level, 25D or 1,25D did not related to NT-pro-BNP
level. cTnT is more sensitive and specific to myocardial injury
than NT-pro-BNP. NT-pro-BNP is dependent on volume
state rather than direct myocardial damage. If vitamin D defi-
ciency causes myocardial injury via above mechanisms, it could
be related more closely to cTnT level than to NT-pro-BNP
level. However, it could not be excluded that the statistical
power of our study might be weak to elucidate the relation-
ship between vitamin D and NT-pro-BNP level.
There are several limitations to this study. First, this is a
cross-sectional study using cardiac biomarkers as surrogates
of CV outcome. Selection bias and residual confounding may
also have contributed to the results. It is possible that the
more malnourished patient had lower vitamin D levels, and
that the increased cTnT levels were associated with antecedent
inflammation-malnutrition syndrome in HD patients. We
measured biochemical parameters only one time. The intra-
and inter-assay coefficient of variation of cTnT were 1.1-3.4%
and 1.7-5.6%, respectively. But the reproducibility of the
observed relationship is still doubtful. Second, we did not
evaluate echocardiographic parameters such as left ventricu-
lar mass index and transmitral flow velocity to mitral annu-
lar velocity ratio (E/E′ ) which reflects left ventricular end dias-
tolic pressure at the time of study. This is major limitation
of the study. If this had been done, understanding the role
of vitamin D in the CV system would have become clearer.
Third, we did not evaluate residual renal function in all par-
ticipants. Because cTnT and NT-pro-BNP level may be affect-
ed by residual renal function, the possibility of confounding
by it should be noted. However, the strength of this study is
in the meticulous patient selection: we included only ambu-
latory patients without documented IHD, CHF, or co-mor-
bidities. Therefore, confounding of vitamin D or cardiac bio-
marker levels by underlying heart disease already existed and
other chronic illness may have been minimal within this study.
In conclusion, the levels of 25D as well as those of 1,25D
are commonly low and correlate poorly with serum calcium,
phosphate, and iPTH in HD patients. The lower 25D lev-
els appear to be associated with cTnT elevation, predicting
worse CV outcome, and is possible to involve cardiac hyper-
trophy or coronary artery disease. The impact of vitamin D
insufficiency on the CV system is important issue in CKD
and further investigation should be required in this regard.
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